CMS finalizes Medicare drug price negotiation rules for 2029 start
CMS finalized permanent Medicare drug price negotiation rules to begin in 2029.
Why it matters: These rules influence drug pricing for Medicare beneficiaries and set compliance standards for healthcare legal teams advising pharmaceutical clients and policy stakeholders.
- CMS formalized the Medicare Drug Price Negotiation Program into permanent rules effective for 2029 start.
- The program targets high-cost, single-source drugs covered under Medicare Parts B and D for negotiated pricing.
- Up to 20 new drugs will be added for negotiation in the program’s fourth and future cycles.
- CMS refined drug eligibility criteria to prevent misuse by modified drug formulations.
- CMS Administrator Dr. Mehmet Oz emphasized the rule’s role in lowering drug costs for seniors.
On June 12, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule cementing the Medicare Drug Price Negotiation Program as a permanent federal policy, with the first negotiation cycle effective for the 2029 price applicability year.
The program allows CMS to negotiate prices for select high-cost, single-source prescription drugs used by Medicare enrollees under Parts B and D. Single-source drugs are those without generic or biosimilar competition, meaning CMS targets medications where price negotiation can yield significant savings.
Under this final rule, CMS plans to add up to 20 negotiation-eligible drugs beginning with the fourth cycle and for subsequent years, increasing the program’s reach and impact over time.
CMS also updated criteria defining qualifying drugs to exclude certain new drug formulations that might have been exploited to avoid negotiation, strengthening program integrity.
Dr. Mehmet Oz, CMS Administrator, stated, "This final rule lowers drug prices for seniors and ensures continued savings." His statement reflects CMS’s objective to make prescription medications more affordable for Medicare beneficiaries.
This regulatory action impacts pharmaceutical pricing strategies and requires legal counsel in healthcare and life sciences to integrate these finalized policies into compliance frameworks and client advisories.
For analysis beyond CMS, legal professionals should monitor commentary from health policy experts and independent watchdog organizations to understand the broader regulatory landscape as the program rolls out.
More information is available on the CMS regulatory guidance page.
By the numbers:
- 2029 — year first Medicare drug price negotiations apply
- Up to 20 — new drugs added for negotiation in program's fourth cycle
- June 12, 2026 — date CMS finalized the pricing negotiation rule
Yes, but: While the rule targets high-cost, single-source drugs, some industry stakeholders express concern about potential impacts on pharmaceutical innovation and product availability.
What's next: Legal and healthcare entities should prepare for advisory updates and compliance reviews ahead of public drug selections expected closer to 2028.